ClinConnect ClinConnect Logo
Search / Trial NCT01668693

ERA Test in Patients With Recurrent Implantation Failure

Launched by IGENOMIX · Aug 16, 2012

Trial Information

Current as of August 23, 2025

Unknown status

Keywords

Endometrial Receptivity Recurrent Implantation Failure Predictor Tool Era Customized Microarray Personalized Embryo Transfer

ClinConnect Summary

Intervention(s): Endometrial sampling, either at LH+7 in a natural cycle or after 5 days of progesterone in a hormonal replacement cycle (HRT) and personalized embryo transfer (pET) on the designated day guided by the ERA prediction.

Repeated implantation failure (RIF) is an unsolved not well characterized major cause of infertility in otherwise healthy women. Although various definitions of RIF exist, the clinical community agrees that after failure of three IVF cycles, in which one to two morphologically high-grade embryos have been transferred, special protocols must be enforced, althou...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Women ≤38 years old
  • Normal ovarian reserve
  • FSH \<8mIU/mL
  • Cycle with ≥6 MII oocytes/oocyte retrieval
  • ≥3 implantation failures in previous IVF/ICSI cycles with transfer of atleast two good quality embryos in each cycle Inclusion Criteria for ovum donation recipients
  • ≥3 implantation failures with transfer of atleast two good quality embryos in each cycle
  • Endometrial thickness ≥ 6 mm
  • Trilaminar pattern after proper progesterone priming
  • Exclusion Criteria:
  • Existance of hydrosalpinx
  • Atrophic endometrium \< 6 mm
  • Previous ectopic or uterine miscarriages
  • Presence of myomas or polyps
  • Previous embryo transfer with high difficulty and/or bleeding

About Igenomix

Igenomix is a leading global biotechnology company specializing in reproductive genetics and advanced genomic solutions. Committed to enhancing reproductive health, Igenomix provides innovative testing services that empower individuals and healthcare providers with critical information for informed decision-making in fertility treatments. With a strong emphasis on research and development, Igenomix leverages cutting-edge technologies to deliver accurate genetic assessments, facilitating personalized approaches to reproductive care. The company's dedication to excellence and patient-centric solutions positions it as a trusted partner in the field of reproductive medicine.

Locations

Valencia, Vaencia, Spain

Patients applied

0 patients applied

Trial Officials

Carlos Simón, MD PhD

Principal Investigator

ºIGENOMIX / IVI Valencia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials